Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omeprazole + amoxicillin + bismuth subcitrate + azithromycin
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a quadruple therapy regimen combining a proton pump inhibitor (omeprazole), two antibiotics (amoxicillin and azithromycin), and bismuth subcitrate. It is used for the eradication of Helicobacter pylori infection. Omeprazole reduces gastric acid secretion to create a favorable environment for antibiotic action. Amoxicillin and azithromycin are broad-spectrum antibiotics targeting bacterial cell wall synthesis and protein synthesis, respectively. Bismuth subcitrate has antibacterial activity against H. pylori and may also protect the gastric mucosa[5][1]. The combination aims to overcome antibiotic resistance by using multiple agents with different mechanisms of action[5].
- Other names
- B-OAzM (in some studies, for bismuth subcitrate, omeprazole, azithromycin, metronidazole; not exact match but similar quadruple therapy)omeprazole-amoxicillin-bismuth-azithromycin combination
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on omeprazole + amoxicillin + bismuth subcitrate + azithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omeprazole + amoxicillin + bismuth subcitrate + azithromycin.